Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000732476 | SCV000860441 | uncertain significance | not provided | 2018-03-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855774 | SCV002281155 | uncertain significance | Gorlin syndrome | 2023-06-14 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 596587). This variant has not been reported in the literature in individuals affected with PTCH2-related conditions. This variant is present in population databases (rs778199787, gnomAD 0.009%). This sequence change creates a premature translational stop signal (p.Arg397Valfs*15) in the PTCH2 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in PTCH2 cause disease. |
Breakthrough Genomics, |
RCV000732476 | SCV005186661 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Fulgent Genetics, |
RCV005021137 | SCV005652177 | uncertain significance | Basal cell carcinoma, susceptibility to, 1; Medulloblastoma | 2024-02-07 | criteria provided, single submitter | clinical testing |